Biotech Values

[bladerunner1717]

Leerink Swann raises price target on ARQL

ArQule Price Target Raised to $5.00 at Leerink Swann (ARQL)
Posted by Scott Davis on Mar 5th, 2015

Research analysts at Leerink Swann lifted their price objective on shares of ArQule (NASDAQ:ARQL) from $4.00 to $5.00 in a research note issued to investors on Thursday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price target suggests a potential upside of 145.10% from the company’s current price.
ArQule (NASDAQ:ARQL) traded up 6.81% during mid-day trading on Thursday, hitting $2.04. The stock had a trading volume of 811,372 shares. ArQule has a 52-week low of $1.04 and a 52-week high of $2.27. The stock’s 50-day moving average is $1.31 and its 200-day moving average is $1.22. The company’s market cap is $128.1 million.

McBio,

I think you forgot to mention in your notes that ARQL will have a FOURTH molecule in the clinic before the end of 2015.


Bladerunner